Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer: A phase II trial

Acta Oncologica

Volumn 42, Issue 4, 2003, Pages 309-314

  Elomaa, Inkeri ^a   Joensuu, Heikki ^a   Blomqvist, Carl ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PATIENT TREATMENT; TOXICITY; TUMORS;

INFECTIONS;

ONCOLOGY;

ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPIRUBICIN; FLUOROURACIL; NAVELBINE; NAVELBINER; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLIC; CONSTIPATION; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; FEMALE; HEART FAILURE; HEART FUNCTION; HUMAN; HUMAN TISSUE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 0038502209     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004373     Document Type: Article

References (23)

1. Norris B, Pritchard KI, James K, et al. Phase III Comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18: 2385-94.
2. Gregory RK, Smith IE. Vinorelbine - a clinical review. Br J Cancer 2000; 82: 1907-13.
3. Spielmann M, Zelek L. Vinorelbine. In: Nabholtz J-M, Tonkin K, Aapro MS, Buzdar AU, BCIRG, eds. Breast cancer management. UK: Martin Dunitz Ltd, 2000: 87-97.
4. Spielmann M, Dorval T, Turpin F, et al. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol 1994; 12: 1764-70.
5. Blomqvist C, Hietanen P, Teerenhovi L, Rissanen P. Vinorelbine and epirubicin in mtetastatic breast cancer. A dose finding study. Eur J Cancer 1995; 31A: 2406-8.
6. Garcia Lopez MJ, Morales S, Conzalez R, et al. Vinorelbine plus adriamycin as first line chemotherapy for advanced breast cancer. Ann Oncol 2000; 11(Suppl 4): 41.
7. Lopez Veva JM, Valladares M, Calvo L, et al. Phase II study with vinorelbine-epirubicin as first line treatment in metastatic breast cancer. Ann Oncol 2000; 11(Suppl 4): 41.
8. Pawlicki M, Rolski J, Siedlecki P, et al. A phase II study of i.v. fractionated vinorelbine and doxorubicin combination in previously untreated advanced breast carcinoma. Ann Oncol 2000; 11(Suppl 4): 40.
9. Piquet D, Fechter E, Buser K. Vinorelbine and fractionated dose of doxorubicin in advanced breast cancer: the Swiss experience. Ann Oncol 2000; 11(Suppl 4): 33.
10. Vici P, Colucci G, Gebbia V, et al. Epirubicin and vinorelbine as first-line chemotherapy in advanced breast cancer. (GOIM-Gruppo Oncologico Italia Meridionale). Ann Oncol 2000; 11(Suppl 4): 33.
11. Esteban E, de Sande G, Puertas J, et al. A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Res Treat 2000; 62: 127-33.
12. Dieras V, Extra JM, Bellisant E, et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 1996; 14: 3097-104.
13. Zambetti M, Demicheli R, De Candis D, et al. Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients. Breast Cancer Res Treat 1997; 44: 255-60.
14. Nole F, de Braud F, Aapro M, et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 1997; 8: 865-70.
15. Goss PE, Fine S, Gelmon K, et al. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPER-FAN) folinic acid in patients with advanced breast cancer. Cancer Chemother Pharmacol 1997; 41: 53-60.
16. Kornek GV, Haider K, Kwasny W, et al. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and 1-leucovorin plus human granulocyte colony-stimulating factor. Br J Cancer 1998; 78: 673-8.
17. Gueler N, Yucel I, ôzet A, et al. Vinorelbine, epirubicin and 5-fluorouracil combination in the first-line treatment of metastatic breast carcinoma (TOG-009 protocol). Ann Oncol 2000; 11(Suppl 4): 33.
18. Blomqvist C, Elomaa I, Rissanen P, et al. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. J Clin Oncol 1993; 11: 467-73.
19. Blajman C, Balbiani L, Block J, et al. A prospective, randomized phase III trial comparing combination chemotherapy with cyclophopshamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 1999; 85: 1091-7.
20. Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Epirubicin and vinorelbine versus single agent epirubicin as first line chemotherapy in metastatic breast cancer. Eur J Cancer 2002; 38(Suppl 3): 111.
21. Namer M, Soler-Michel P, Turpin F, et al. Prospective randomized study comparing mitoxantrone (M) and vinorelbine (V) with fluorouracil (F), epirubicin (E) or Adriamycin (A) and cyclophosphamide (C) in patients with metastatic breast cancer. Eur J Cancer 2001; 37: 1132-40.
22. Bonneterre J, Roche H, Monnier A, et al. Taxotere (TXT) versus 5-fluorouracil+Navelbine (FUN) as second-line chemotherapy (CT) in patients (pts) with metastatic breast cancer (MBC) (preliminary results). Proc Am Soc Clin Oncol 1997; 16: A564.
23. Whelan TJ, Julian J, Wright J, et al. Does locoregional radiation therapy improve survival in breast cancer? A Metaanalysis. J Clin Oncol 2000; 18: 1220-9.